FOSTER CITY, Calif.--(BUSINESS WIRE)--Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, today announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
“These two clinical projects provide further validation of the Notable predictive precision medicine platform. The exciting data advance our mission to design and deliver predictive precision medicines by matching treatments with precisely the patients who clinically respond to them,” says Joe Wagner, PhD, Chief Scientific Officer of Notable.
The meeting will be held virtually and in person in Atlanta, GA, from December 11-14, 2021.
Abstract details:
-
Title: Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib As a Potential Novel Drug Combination for Pediatric AML
Publication Number: 2361
Submission ID: 145275
Authors: Debbie Strachan, Ph.D. et al.
Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Poster Presentation Date and Time: Sunday, December 12, 2021, 6:00 PM-8:00 PM
Location: Georgia World Congress Center, Hall B5
-
Title: Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay
Publication Number: 3464
Submission ID: 148891
Authors: Markus Lacher, Ph.D. et al.
Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Poster Presentation Date and Time: Monday, December 13, 2021, 6:00 PM-8:00 PM
Location: Georgia World Congress Center, Hall B5
The posters will be available for viewing on December 11, 2021 at 9 a.m. ET and will be available on Notable’s website following their presentations.
For more details about the ASH Annual Meeting please visit: https://www.hematology.org/meetings/annual-meeting
About Notable
Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.
Notable’s proprietary predictive precision medicines platform bio-simulates a patient’s cancer treatment and predicts whether a patient will respond to a specific cancer treatment. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.
Investors in Notable include B Capital Group, Lifeforce Capital, Builders VC, Founders Fund, Lightspeed Venture Partners, Y Combinator, First Round Capital as well as 11.2 Capital, Refactor Capital, Upside Partnership, and Fuel Ventures.
Notable is headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.
